Discover Great Companies Discover Great Clients
Popularity  1.9万   |   Followers  7   |   Likes  24   |   Feedback  6 Claim this company
No.60 Jiulongpo District Popularity Ranking Chongqing No.14 Pharmaceutical R&D No.15 Biological Products No.16 Biopharmaceuticals No.19 Sheng Wu Ke Ji / Biotechnology Engineering No.22 Pharmaceutical Technology No.22 Gong Cheng Yan Jiu Center No.22 Lin Chuang Yi Xue No.24 Healthcare Technology No.25 Yao Products R&D No.32 Zhi Yao / Yao Industries No.39 Pharmaceutical No.51 Pharmaceutical Industrial 博士后工作站 院士工作站 科技型中小企业 省级创新型中小企业 市级专精特新中小企业 市级创新型中小企业
More

Company Overview

  • Nature: Private Enterprise Size: 100-499 employees Founded: 10年
  • Industry: Pharmaceutical/Bioengineering 、 Raw Materials and Processing
  • Full name: Chongqing Precision Biotechnology Co., Ltd.。

Development Stage

  • Honors: 博士后工作站 院士工作站 According to algorithm
  • Salary: 57.4% of positions earn 8-15K, In 2026 vs last yeargrew by 14%.。Master's salary: ¥16.6K.
  • R&D: "Medical & Health/Beauty & Healthcare" demand: 39.1%, "Biology/Pharmaceutical/Chemical/Environmental Protection": 14.9%, "Other (R&D and Technical)": 13.8%。
  • Recruiting: In 2026 vs 2025decreased by 14%. Demand for highly educated talent: Master's: 2.
  • Requirement: Education: 本科 leads with 73.6%. Experience: 1-3年 leads with 50.6%.
  • Region: Distributed across 3 regions, 重庆: 70.1%, 北京: 5.7%, 成都: 5.7%, 苏州: 4.6%.

About the Company

Chongqing Precision Biotechnology Co., Ltd. (hereinafter referred to as the Company) was established in 2016. It is a high-tech enterprise jointly founded by the technical team led by Professor Qian Cheng, a renowned scientist in precision medicine, and the listed company Zhifei Biological (Zhirui Investment). The Company takes gene and cell therapy technologies as its entry point, focuses on the development and application of CAR-T cell drugs, and is committed to building a global innovative biopharmaceutical enterprise.
The Company has established an Industrial Technology Research Institute, a Postdoctoral Workstation, and a Overseas Expertise Introduction Workstation, and has been approved for platform qualifications such as Chongqing New High-end R&D Institution, Key Laboratory, Engineering Research Center, and Engineering Technology Research Center; it has built a 15,700-square-meter fully equipped and powerful cell drug IND and NDA platform, possessing highly intelligent production lines for plasmid, vector, and cell preparation and an online testing and quality control platform. It is a public service platform for biopharmaceutical R&D specially supported by the National Development and Reform Commission, the Ministry of Science and Technology, and others; the Company has gathered more than 20 domestic and international experts and masters, currently has 289 employees, and has assembled 223 R&D elite team members (including 53 master's and doctoral students); through independent research and development, the Company has mastered core technologies in the field of cell therapy and possesses cutting-edge key technologies such as future universal CAR-T and solid tumor CAR-T, has applied for 62 invention patents for core key technologies, obtained 16 domestic and international patent authorizations, and has made special arrangements in developed regions such as Europe and America; the Company has obtained implied licenses for two CAR-T cell Class I biological new drugs and five indications, covering multiple myeloma, pediatric and adult leukemia, lymphoma, and renal cancer among solid tumors. The registered clinical trials are progressing smoothly and have achieved excellent clinical data; the Company has laid out more than 10 CAR-T R&D pipelines for leukemia, lymphoma, myeloma, lymphoma, gastrointestinal cancer, lung cancer, liver cancer, breast cancer, pancreatic cancer, etc., and has already made breakthrough progress. Indications such as colorectal cancer, gastric cancer, and breast cancer have entered the registered clinical application stage, and a global leading breakthrough in the field of CAR-T technology for solid tumors is about to be achieved; while preparing to build a cell new drug manufacturing base in China, the enterprise is also actively promoting the globalization strategy for the transformation and application of achievements. It has successively reached agreements with multiple institutions in Europe and America, established overseas R&D branches, and expanded its international market commercial layout; in the next 3 to 5 years, the enterprise strives to achieve the market launch of more than 3 Class I cell new drugs, with annual sales revenue exceeding 20 billion yuan.

Expand
Information is aggregated from the web and may not be exact. For reference only.
Information incorrect? Claim this company to edit

How Fast Is Hiring Growing? (22 open positions)

Manage
?
Growth Rate
2026 vs 2025
  • 2025: Up 152%
  • 2024: Down 14%
  • 2023: Up 33%
  • 2022: Down 63%
Year-by-Year Hiring:
* Hiring was generally low during 2020-2022 due to the pandemic
Campus Recruitment & Advanced Degree Talent Demand
Master's 2
Note: How fast is hiring at Chongqing Precision Biotechnology Co., Ltd. growing? 2026: 67 openings (down 14%), 2025: 78 openings (up 152%), 2024: 31 openings (down 14%), 2023: 36 openings (up 33%), 2022: 27 openings (down 63%), 2021: 72 openings. A rising curve may indicate expansion; a falling curve may indicate slower growth or good retention. Based on publicly available data, for reference only.

Master's Degree Job Demand Analysis

(More)
?
Growth Rate
2026 vs 2025
  • 2025: Up 20%
  • 2024: Up 67%
  • 2023: Flat 0%-
  • 2022: Up 50%
Master's Hiring by Year:
* Hiring was generally low during 2020-2022 due to the pandemic
How fast is master's hiring at Chongqing Precision Biotechnology Co., Ltd. growing? Master's recruitment over the years: 2025: 6 openings (up 20%), 2024: 5 openings (up 67%), 2023: 3 openings (flat), 2022: 3 openings (up 50%), 2021: 2 openings.

Doctoral Degree Job Demand Analysis

(More)
N/A
Growth Rate
Doctoral Hiring by Year: 2025
* Hiring was generally low during 2020-2022 due to the pandemic
How fast is doctoral hiring at Chongqing Precision Biotechnology Co., Ltd. growing? Doctorate recruitment over the years: 2025: 1 openings (up 20%), 2023: 1 openings (flat), 2022: 1 openings (up 50%), 2021: 2 openings.

R&D Strength (Technical Talent Demand)

(More)
How is the demand for technical talent at Chongqing Precision Biotechnology Co., Ltd.? Based on an analysis of 's job postings over the past year, "Medical & Health/Beauty & Healthcare" demand: 39.1%, "Biology/Pharmaceutical/Chemical/Environmental Protection": 14.9%, "Other (R&D and Technical)": 13.8%, "Scientific Research": 2.3%. For reference only.

— What Are the Salaries Like? (87 records)

Manage
salary range: 4.5K - 50K, 57.4% of roles pay ¥8-15K
Note: salary statistics are based on 87 salary records from the past year and depend on the job sample. For reference only.
How is the salary at Chongqing Precision Biotechnology Co., Ltd.?57.4% of positions earn 8-15K, Undergraduate salary: ¥。Chongqing salary ranking top 25,销售类 average salary ¥16.0K。 Note: Based on analysis of job postings, does not represent current on-the-job positions; system stability may affect objectivity. For reference only.Data inaccurate? Let us know

Salaries for hot jobs of

(More)
Are salaries high at Chongqing Precision Biotechnology Co., Ltd.? We provide: Sales, Account Manager, 临床, R&D Assistant, Medical Manager, 医学专员, Regional Manager, Operations, MA, QC, RA, Business Development, Medical Assistant, Medical Science Liaison, Marketing, Technical Support, Research Assistant, Researcher, Equipment Management Specialist, Quality. Click to view detailed salary analysis by job.

Job Category

  • 销售类
    48.3% of total 48.3%
  • 医疗卫生/美容保健类
    39.1% of total 39.1%
  • 客户服务类
    25.3% of total 25.3%
  • 工厂生产类
    21.8% of total 21.8%

Education

  • 本科
    73.6% of total 73.6%
  • 硕士
    16.1% of total 16.1%
  • 大专
    9.2% of total 9.2%
  • 初中
    1.1% of total 1.1%

Experience

  • 1-3年
    50.6% of total 50.6%
  • 3-5年
    32.2% of total 32.2%
  • 不限
    11.5% of total 11.5%
  • 5-10年
    5.7% of total 5.7%
View Detailed Analysis

What does Chongqing Precision Biotechnology Co., Ltd. require? Who is Chongqing Precision Biotechnology Co., Ltd. hiring? recruitment: 销售类占比最多占48.3%,其次是医疗卫生/美容保健类占39.1%. What education can get in at ? 本科占比最多占73.6%,其次是硕士占16.1%. High education required at ? 硕士占16.1%. Work experience required at ? 1-3年占比最多占50.6%,其次是3-5年占32.2%. Where are the job locations at ? 重庆占比最多占70.1%,其次是北京占5.7%. Based on job postings from the past year, for reference only.

Business Registration

Provided by

Operating Status: 开业
Registered Capital: 1,259.0019万(元)
Legal Representative: 钱程
Date Established:
Credit Code: 91500107MA5U4AUN1H
Registered Address: 重庆市九龙坡区含谷镇含兴路38号

Partners & Suppliers

共同推进CAR-T细胞治疗消化道肿瘤的临床研究。 Source
供应商 临床研究
合作开展CAR-T细胞治疗淋巴瘤等疾病的临床研究。 Source
供应商 临床研究
共同开展CAR-T细胞治疗血液肿瘤和实体瘤的临床研究。 Source
供应商 临床研究
合作开展CAR-T细胞治疗实体瘤的临床试验。 Source
供应商 临床研究
双方签署战略合作协议,共同推进儿童白血病等疾病的CAR-T细胞治疗临床研究。 Source
供应商 临床研究

People who follow this company also follow

Competitors (Similar Companies)

租赁 融资租赁 财务咨询 外商投资
研究院/研究所 科技期刊 地质 环保/节能
电子商务 供应链管理 汽车生活 遮阳挡
企业管理 生产 项目管理咨询 实训基地
咨询 工程咨询 国际工程 东南亚跨境电商
ODM 制造 生产 智能硬件
业务流程外包 人力资源/HR外包 劳务外包 服务外包
物业 檀香 办公空间 社区管理
医药 制药/药业 药品零售 批发
空气净化设备 空气净化器 净化设备 气体净化
炉窑 熔炼炉 生产 热工设备
纯水机 纯水设备 超纯水机 研发
“Building an open platform for the Internet of Things”
计算机服务 数据服务 大数据 ERP

Discover Great Companies, Discover Great Clients

重庆公司名录 重庆“Jiulongpo District”公司名录 重庆“生物科技/生物工程”公司名录 重庆“医药”公司名录 重庆“生物医药”公司名录 重庆“医疗科技”公司名录 重庆“生物制品”公司名录 附近的公司

Report

*Reason:

Radical political or ideological topics
Advertising or spam
Pornographic or vulgar content
Obscene language or personal attacks
Other

Congratulations, submitted successfully!

Your edit is under review. You will be notified by email within 1 business day.

Submission failed.

Followed successfully. We'll notify you of any company updates.

Help others learn about this company, add my impression of this company»

Log in with the following accounts to save your follows

Followed successfully, we'll notify you of any company updates